This comprehensive review examines the efficacy and safety of tumor necrosis factor-alpha (TNF-α) inhibitors in treating various autoimmune diseases, and focuses on their application in Iraqi patients. Elevated TNF-α levels are linked to autoimmune disorders, leading to the development of anti-TNF-α therapies such as infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab, which have gained FDA approval for conditions like psoriasis, inflammatory bowel disease, ankylosing spondylitis, and rheumatoid arthritis. While these therapies demonstrate significant therapeutic benefits, including improved quality of life and disease management, they also carry risks, such as increased susceptibility to infections and potential malignancies. The review highlights the variable patient responses to TNF-α inhibitors, influenced by pharmacokinetic and pharmacodynamic factors as well as genetic variations. The rise of anti-drug antibodies and inadequate drug concentrations are common challenges observed, emphasizing the need for therapeutic drug monitoring. Safety profiles of TNF-α inhibitors are generally favorable, but adverse effects (including infections and infusion reactions) have been reported. Genetic factors, such as polymorphisms in the TNF-α gene, may also play a role in the treatment responsiveness and adverse effects, suggesting the potential for personalized medicine approaches. While TNF-α inhibitors effectively manage autoimmune diseases in Iraqi patients, further research is warranted in order to optimize treatment strategies, assess long-term safety, and explore genetic influences on therapy outcomes. The findings underscore the importance of individualized treatment plans so as to enhance the efficacy and minimize the risks associated with these biologic therapies.